

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of  
1934

December 4, 1996

-----  
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Exact name of registrant as specified in its charter)

Delaware	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction or organization)	(Commission File Number)	(IRS Employer Identification Number)

358 South Main Street, Burlington, North Carolina 27215

-----  
(Address of principal executive offices)

910-229-1127

-----  
(Registrant's telephone number, including area code)

#### Item 5. Other Events

On December 4, 1996, the Company issued a press release announcing the resignation of David C. Weavil, Executive Vice President and Chief Operating Officer and that Ronald B. Sturgill, Executive Vice President, is assuming responsibilities as Chief Operating Officer until a successor is named. The press release is attached as an exhibit hereto and the text thereof is incorporated in its entirety herein by reference.



Item 7. Financial Statements, Pro Forma Financial  
Information and Exhibits

(c) Exhibits

20 Press release of the Registrant dated December 4, 1996.



SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----  
(Registrant)

By: /s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President, General  
Counsel and Secretary

Date: December 4, 1996







FOR IMMEDIATE RELEASE

Contact: Pamela Sherry

Telephone: (910) 584-5171

Ext. 6768

LABORATORY CORPORATION OF AMERICA ANNOUNCES RESIGNATION OF DAVID  
C. WEAVIL, EVP AND COO

Burlington, NC, December 4, 1996 -- Laboratory Corporation of America Holdings (LabCorp) (NYSE: LH) today announced the resignation of David C. Weavil, Executive Vice President and Chief Operating Officer, effective immediately. Mr. Weavil's resignation came as a result of LabCorp's recently announced government settlement, and resolves all issues related to 1993-initiated federal investigations of prior billing practices for LabCorp's predecessor companies. These investigations, which were part of a broad-based inquiry into industry-wide billing practices, have resulted in settlements with a number of other clinical laboratories to date and are expected to result in additional settlements in the near future.

Ronald B. Sturgill, Executive Vice President, is assuming responsibilities as Chief Operating Officer until a successor is named. Mr. Sturgill, whose current responsibilities include Human Resources and the South Atlantic Operating Division, is a 25-year veteran of the Company and the clinical laboratory industry.

Laboratory Corporation of America Holdings (LabCorp) is a national clinical laboratory organization with estimated annualized revenues of \$1.6 billion. The Company operates primary testing facilities nationally, offering more than 1,700 different clinical assays, from routine blood analysis to more sophisticated technologies. LabCorp performs diagnostic tests for physicians, managed care organizations, hospitals, clinics, long-term care facilities, industrial companies and other clinical laboratories.

###